44O Pembrolizumab (pembro) vs chemotherapy (chemo) for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-119 Asia-Pacific subpopulation

S-a. Im, Javier Cortés, Oleg Lipatov, Anthony Gonçalvès, Ks Lee, Peter Schmid, Kenji Tamura, Laura Testa, I Witzel, Shoichiro Ohtani, Stefania Zambelli, Nadia Harbeck, Fabrice André, Rebecca Dent, J. Lin, Vassiliki Karantza, Jaime Mejia, Eric P. WinerAnnals 2020 · DOI

BibTeX
@article{im2020o,
  author = {S-A. Im and Javier Cortés and Oleg Lipatov and Anthony Gonçalvès and KS Lee and Peter Schmid and Kenji Tamura and Laura Testa and I Witzel and Shoichiro Ohtani and Stefania Zambelli and Nadia Harbeck and Fabrice André and Rebecca Dent and J. Lin and Vassiliki Karantza and Jaime Mejia and Eric P. Winer},
  title = {{44O Pembrolizumab (pembro) vs chemotherapy (chemo) for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-119 Asia-Pacific subpopulation}},
  journal = {Annals},
  year = {2020},
  doi = {10.1016/j.annonc.2020.10.064},
}

Loading related content...

Figure